What is the market capitalization of ARCH BIOPARTNERS INC?

ARCH BIOPARTNERS INC (ARCH.V) has a market capitalization of approximately 32,268,312 CAD.

Where can I buy ARCH.V in Canada?

ARCH.V can be purchased through any Canadian online broker including Wealthsimple, Questrade, Qtrade, or RBC Direct Investing.

ARCH.V

ARCH BIOPARTNERS INC

ARCH BIOPARTNERS INC (ARCH.V) is a Canadian company in the healthcare sector, listed on TSXV. Market capitalization of 32 million CAD (micro-cap).

Details

Price0.47 CAD

Market cap32.27 M CAD

Payout ratio0.00%

Next ex-dateSep 13, 2000

SectorHealthcare

Websitearchbiopartners.com

Updated 1h ago

Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related acute kidney injury via dipeptidase-1. The company also develops CKD Platform, therapeutics targeting chronic kidney disease. Arch Biopartners Inc. is based in Toronto, Canada.